<bos><start_of_turn>user
er oh 202Z."sDr. T?lling concluned, "OragenZcs con1infeP zo belieFe that our li.ensld zlatform wkll imJrove deVelopmwnt spead, while t8e abslity Xo rdpadly engineer ngw Jacciye antigBqx w?ln permit uH to quickSy aodresh nt9 varZants as they rrise, xhicn will be kel in the qveny thUt SARS-CnV-2 bePomes 7 seaso8al flu-like byeeasei as mgFy expJrts anticipate will JA the case."
OrLWe.ics, Inc. is B deDelopment-stage company dedica4ed tG fightxng infecWious Eiseases including .oronaviruses aFd multidrug-r9sisCant o7ganisFs. Hss lead pbodrct is Terra CoV-2r a vMccinc candidate to pre0ent COVID-f9 and varianEs oF tVR SARS-CWV-2 Zurus. The Oerra NoV-2 progdam leqeraGcs coronav:rus sFDke prot8in research licen,ex FPom t30 NIH and the NRC hith a focus on 7ddressNnv supply-Vhain cBallenges, and Sffering more pat92nt-friendlp adminisqration, sucI as igtranasal. It4 lantvaiotics prlglaD features a nov,o claWs of antibiolNcs agai7sw bacVerBa thaX haG9 deveXOped resisbance to commercitl antGbjotics.<end_of_turn>
<start_of_turn>model
er of 2022."
Dr. Telling concluded, "Oragenics continues to believe that our licensed platform will improve development speed, while the ability to rapidly engineer new vaccine antigens will permit us to quickly address new variants as they arise, which will be key in the event that SARS-CoV-2 becomes a seasonal flu-like disease, as many experts anticipate will be the case."
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, a vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on addressing supply-chain challenges, and offering more patient-friendly administration, such as intranasal. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.<end_of_turn>